Weight-Loss Drug Boom Threatens Global Insulin Supply, Experts Warn

RecentNews.uk

The commercial boom in GLP-1 weight-loss drugs risks diverting pharma investment away from insulin production.

Manufacturers enjoy higher profit margins on weight-loss injections compared to traditional diabetes medicines.

An estimated 589 million adults live with diabetes globally, with the vast majority in low- and middle-income nations.

Novo Nordisk has already announced plans to phase out some older diabetes products including insulin pens.

Should pharmaceutical companies be legally required to maintain basic insulin production alongside weight-loss drugs?

Tap below to vote and see what others think.